Tiumbio Co Ltd. has described bromodomain-containing protein 4 (BD2 domain) (BRD4 BD2) inhibitors reported to be useful for the treatment of cancer, fibrosis, diabetes, metabolic syndrome, and renal ...

Investigators at the Third People’s Hospital of Chengdu and collaborators described the synergistic effect obtained by the combined administration of LB-23, a PARP1 degrader, and JQ1, a BRD4 inhibitor ...